Growth Metrics

Crescent Biopharma (CBIO) Preferred Stock Liabilities (2024 - 2025)

Crescent Biopharma (CBIO) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $4.0 million as the latest value for Q1 2025.